問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

林晏年
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林晏年

List

34Cases

2025-10-01 - 2030-06-30

Active
EASi-PROTKT™ is a phase III, double-blind, randomized, parallel-group superiority trial evaluating the efficacy and safety of oral vicadrostat (BI 690517) combined with empagliflozin compared to placebo combined with empagliflozin in participants with type 2 diabetes, hypertension, and a history of cardiovascular disease.

  • Condition/Disease

    • The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.

  • Test Drug

    BI 690517 (Vicadrostat) or matching placebo Empagliflozin

Participate Sites
13Sites

Recruiting13Sites

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2025-03-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2024-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
20Sites

Not yet recruiting11Sites

Recruiting8Sites

2025-07-01 - 2030-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2021-05-01 - 2025-12-31

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting12Sites

2023-10-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting5Sites

2024-02-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2022-06-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB